Advertisement

Advertisement
Kidney Cancer

Addition of Nivolumab to Tivozanib Following Immune Checkpoint Inhibitor Treatment in Metastatic Renal Cell Carcinoma

As reported in The Lancet by Choueiri et al, the phase III TiNivo-2 trial reported results of the immune checkpoint inhibitor rechallenge with nivolumab plus tivozanib vs tivozanib alone in patients with metastatic renal cell carcinoma following immune checkpoint inhibitor treatment.


Head and Neck Cancer

Standard Chemoradiation May Be Superior to Deintensification Approaches in Patients With HPV-Associated Oropharyngeal Cancer

Deintensified treatment involving a lower radiation dose and immunotherapy in place of chemotherapy may not perform as well as a more rigorous chemoradiation treatment approach in patients with early-stage human papillomavirus (HPV)-associated oropharyngeal cancer, according to new findings presented by Yom et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA03) and simultaneously published in the International Journal of Radiation Oncology • Biology • Physics.

 

Breast Cancer

ACS Report: Despite Overall Decreases in Breast Cancer Mortality, Incidence Rising in Key Groups

The American Cancer Society (ACS) released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately 517,900 breast cancer deaths. However, not all women have benefited from this progress, notably American Indian and Alaska Native (AIAN) women, whose rates have remained unchanged over the past 3 decades. Also concerning is the continued upward trend in breast cancer incidence, rising by 1% annually during 2012–2021, with the steepest increase in women younger than 50 years (1.4% per year) and Asian American/Pacific Islander (AAPI) women of any age (2.5%–2.7% per year). These findings were reported by Giaquinto et al in CA: A Cancer Journal for Clinicians


Advertisement
Prostate Cancer

Intensity-Modulated Radiation Therapy and Proton-Beam Therapy May Offer Equally High Quality of Life and Tumor Control in Patients With Localized Prostate Cancer

Two types of contemporary radiation therapy—proton-beam therapy or intensity-modulated radiation therapy—may provide comparable rates of tumor control with no differences in patient-reported quality of life among patients with low- and intermediate-risk prostate cancer, according to new findings presented by Efstathiou et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA01) and simultaneously published in the International Journal of Radiation Oncology • Biology • Physics.

 

Breast Cancer

Neo-CheckRay: Adding Durvalumab to Neoadjuvant Regimen Improves Pathologic Complete Response Rate in High-Risk Breast Cancer

Adding the immune checkpoint inhibitor durvalumab, with or without the monoclonal antibody oleclumab, to neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) significantly improved pathologic complete response rates in patients with high-risk hormone receptor (HR)-positive breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.

Advertisement
Advertisement




Sponsored Content

More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Lung Cancer

Amivantamab-vmjw Plus Lazertinib Improves Long-Term Outcomes in First-Line Setting of EGFR-Mutant Advanced NSCLC

The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...

Advertisement

Certain KRAS Gene Mutations Linked to Improved Prognosis in Pancreatic Cancer

A common mutation in the KRAS gene seems to be associated with improved overall survival in pancreatic ductal adenocarcinoma compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a recent study published in...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Gynecologic Cancers

Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer

On April 29, 2024, tisotumab vedotin-tftv (Tivdak) was granted regular approval for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.1 Tisotumab vedotin is a tissue factor–directed antibody and microtubule inhibitor conjugate. The agent was granted...

Solid Tumors
Issues in Oncology
Hematologic Malignancies

The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 2

Vincent T. DeVita, MD George P. Canellos, MD Medical oncology had a turbulent beginning, as we explained in part 1 of this commentary published in the September 25, 2024, issue of The ASCO Post. And although no other specialty we know of struggled as much, with perseverance and time, it...

FDA Approves Perioperative Nivolumab for Resectable NSCLC

On October 3, 2024, the U.S. Food and Drug Administration approved nivolumab (Opdivo) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node-positive) non–small cell...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Skin Cancer

A Clinical Trial Has Halted Progression of Merkel Cell Carcinoma and Allowed Me to Pursue My Love of Music

Vincent DiMartino At the age of 75, I’m just happy to still be here and be able to continue to contribute to my musical community. When I was diagnosed with Merkel cell carcinoma in 2021, I had never heard of the cancer and didn’t realize how aggressive and deadly it is. It was especially...

Advertisement

Autologous vs Allogeneic Stem Cell Transplantation in Younger Patients With Peripheral T-Cell Lymphoma: 7-Year Follow-up

In an analysis reported in the Journal of Clinical Oncology, Tournilhac et al identified 7-year outcomes of the phase III AATT trial evaluating autologous vs allogeneic transplantation in younger patients with peripheral T-cell lymphoma. Study Details In the trial, 103 patients (aged 18–60) from...

ASCO Post X Feed
Social Media Hub by Everwall